B-cell Lymphoma Refractory Clinical Trials

8 recruitingLast updated: June 18, 2026

There are 8 actively recruiting b-cell lymphoma refractory clinical trials across 6 countries. Studies span Phase 1, Phase 2. Top locations include Beijing, Beijing Municipality, China, Boston, Massachusetts, United States, Columbus, Ohio, United States. Updated daily from ClinicalTrials.gov.


B-cell Lymphoma Refractory Trials at a Glance

8 actively recruiting trials for b-cell lymphoma refractory are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 1 with 6 trials, with the heaviest enrollment activity in Beijing, Boston, and Columbus. Lead sponsors running b-cell lymphoma refractory studies include GenomeFrontier Therapeutics TW Co., Ltd., Jennifer Crombie, MD, and Daihong Liu.

Browse b-cell lymphoma refractory trials by phase

Treatments under study

About B-cell Lymphoma Refractory Clinical Trials

Looking for clinical trials for B-cell Lymphoma Refractory? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new B-cell Lymphoma Refractory trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about B-cell Lymphoma Refractory clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 1

A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies

Follicular Lymphoma ( FL)Diffuse Large B Cell Lymphoma RefractoryPrimary Mediastinal Large B-Cell Lymphoma Refractory+3 more
GenomeFrontier Therapeutics TW Co., Ltd.18 enrolled1 locationNCT06703892
Recruiting
Phase 1Phase 2

Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma

CNS MetastasesB-cell Lymphoma RecurrentB-cell Lymphoma Refractory
Samsung Medical Center37 enrolled2 locationsNCT06552559
Recruiting
Phase 1Phase 2

Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas

B-cell Lymphoma Refractory
National University Hospital, Singapore30 enrolled1 locationNCT07319676
Recruiting
Phase 2

Pembro Plus CAR T-cell Therapy in R/R in PMBCL

Primary Mediastinal Large B Cell LymphomaPrimary Mediastinal Large B-cell Lymphoma (PMBCL)Primary Mediastinal Large B-Cell Lymphoma Refractory+3 more
Jennifer Crombie, MD35 enrolled2 locationsNCT05934448
Recruiting
Phase 1

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

Diffuse Large B-cell Lymphoma RecurrentDiffuse Large B Cell Lymphoma RefractoryTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma+8 more
Nathan Denlinger18 enrolled1 locationNCT06209619
Recruiting
Phase 2

Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia

B-cell Lymphoma Refractory
Daihong Liu10 enrolled1 locationNCT07321301
Recruiting
Phase 1

Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies

Acute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic Leukemia RefractoryB-cell Lymphoma Recurrent+3 more
Nelson Hamerschlak30 enrolled1 locationNCT05705570
Recruiting
Phase 1

CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL

Acute Lymphoblastic Leukemia, in RelapseB-cell Lymphoma RecurrentB-cell Lymphoma Refractory+1 more
Rong Tao48 enrolled2 locationsNCT06445803